Seres Therapeutics Inc. (MCRB) Stock Price Up 14.6%
Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price rose 14.6% during trading on Tuesday . The company traded as high as $14.49 and last traded at $14.38, with a volume of 1,474,671 shares traded. The stock had previously closed at $12.55.
MCRB has been the topic of a number of research reports. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a report on Friday, July 29th. HC Wainwright initiated coverage on Seres Therapeutics in a report on Friday, July 29th. They issued a “buy” rating and a $50.00 price objective on the stock. Canaccord Genuity restated a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a report on Monday, August 1st. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 19th. Finally, FBR & Co decreased their target price on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a research report on Friday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $31.57.
The firm’s market capitalization is $578.33 million. The firm’s 50 day moving average is $11.00 and its 200-day moving average is $24.21.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The firm earned $3 million during the quarter, compared to analyst estimates of $4.20 million. During the same quarter in the previous year, the business earned ($1.45) EPS. Seres Therapeutics’s quarterly revenue was up NaN% compared to the same quarter last year. Equities analysts anticipate that Seres Therapeutics Inc. will post ($2.32) EPS for the current fiscal year.
In other news, insider John G. Aunins sold 9,390 shares of Seres Therapeutics stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $34.18, for a total transaction of $320,950.20. Following the transaction, the insider now owns 220,155 shares in the company, valued at approximately $7,524,897.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michele Trucksis sold 4,156 shares of Seres Therapeutics stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $35.18, for a total value of $146,208.08. Following the completion of the sale, the insider now directly owns 4,156 shares in the company, valued at approximately $146,208.08. The disclosure for this sale can be found here. Insiders own 41.90% of the company’s stock.
A number of large investors have recently made changes to their positions in MCRB. Flagship Ventures Fund IV L.P. purchased a new stake in shares of Seres Therapeutics during the first quarter worth about $374,060,000. DekaBank Deutsche Girozentrale raised its stake in shares of Seres Therapeutics by 20.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,300 shares of the company’s stock worth $606,000 after buying an additional 3,500 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Seres Therapeutics by 8.2% in the first quarter. BlackRock Fund Advisors now owns 716,515 shares of the company’s stock worth $19,031,000 after buying an additional 54,438 shares in the last quarter. Flagship Ventures Fund 2007 L.P. purchased a new stake in shares of Seres Therapeutics during the first quarter worth about $15,917,000. Finally, Sabby Management LLC raised its stake in shares of Seres Therapeutics by 556.0% in the first quarter. Sabby Management LLC now owns 69,287 shares of the company’s stock worth $1,840,000 after buying an additional 58,725 shares in the last quarter. 78.28% of the stock is currently owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.